» Articles » PMID: 20216125

Osteonecrosis in Patients After Severe Acute Respiratory Syndrome (SARS): Possible Role of Anticardiolipin Antibodies

Overview
Date 2010 Mar 11
PMID 20216125
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study examined the anticardiolipin antibodies in post-SARS (severe acute respiratory syndrome) osteonecrosis patients to investigate the etiology of post-SARS osteonecrosis, and to eventually provide valuable information for the early diagnosis of nontraumatic osteonecrosis and for the susceptible population screening.

Methods: This study recruited 62 post-SARS osteonecrosis patients and 52 age- and gender-matched healthy controls. Fasting blood samples were collected from all the subjects through cubital veins. Immunoglobulins A, G and M (IgA, G and M) types of anticardiolipin antibodies were examined by enzyme-linked immunosorbent assay. The routine examinations of prothrombin time, thrombin time, prothrombin activity, and international normalized ratio were also performed.

Results: There were 21 of 62 post-SARS osteonecrosis patients (33.9%) who showed at least one type of anticardiolipin antibodies. The titers of specific IgA, IgG, and IgM were 11.33 +/- 11.209 APL, 5.127 +/- 5.927 GPL, and 17.821 +/- 10.606 MPL, respectively. There were only 4 of 52 subjects in the control group (7.7%) who showed positive anticardiolipin antibody with titers of IgA at 10.702 +/- 3.126 APL, IgG at 5.184 +/- 4.780 GPL, and IgM at 14.684 +/- 5.516 MPL. There were significant differences between the 2 groups confirmed by t-Test and chi(2) test (P < 0.05), while no significant differences were observed in prothrombin time, thrombin time, prothrombin activity, and international normalized ratio results between the 2 groups.

Conclusions: The incidences of anticardiolipin antibodies were increased in the post-SARS osteonecrosis patients and anticardiolipin antibodies may play a role in the pathogenesis of post-SARS osteonecrosis.

Citing Articles

The Impact of COVID-19 Infection on the Development of Stroke, Pulmonary Embolism, and Myocardial Infarction: A Retrospective Study.

Guven O, Karakurt G, Naser A, Selcuk H, Keles D, Gedik E Cureus. 2025; 17(1):e77665.

PMID: 39968441 PMC: 11835032. DOI: 10.7759/cureus.77665.


General recommendation for assessment and management on the risk of glucocorticoid-induced osteonecrosis in patients with COVID-19.

Li W, Huang Z, Tan B, Chen G, Li X, Xiong K J Orthop Translat. 2021; 31:1-9.

PMID: 34692412 PMC: 8526281. DOI: 10.1016/j.jot.2021.09.005.


Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots.

Tung M, Tan B, Cherian R, Chandra B Rheumatol Adv Pract. 2021; 5(1):rkaa081.

PMID: 33615129 PMC: 7882149. DOI: 10.1093/rap/rkaa081.


A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.

Huang A, Garcia-Carreras B, Hitchings M, Yang B, Katzelnick L, Rattigan S Nat Commun. 2020; 11(1):4704.

PMID: 32943637 PMC: 7499300. DOI: 10.1038/s41467-020-18450-4.


Late acute pulmonary embolism after mild Coronavirus Disease 2019 (COVID-19): a case series.

Vechi H, Maia L, do Monte Alves M Rev Inst Med Trop Sao Paulo. 2020; 62:e63.

PMID: 32901760 PMC: 7477961. DOI: 10.1590/S1678-9946202062063.